Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
+$1.20 today
- Market cap
- $56.67M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
Volume 0.15M
Average 0.22M
BOLD Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Boundless Bio, Inc.NASDAQ: BOLD
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$284K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$1.22M.
Context
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$284K or moves back toward the trailing-twelve-month quarterly average of -$304.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (1.25M) USD
- Year-over-year change
- -15.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.25M) | -15.2% |
| FY2024 | 2024-12-31 | (1.09M) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Gross Profit vs competitors
How BOLD compares with its peers on the latest reported figures
- BOLD's LTM Mar 2026 gross profit of -$1.22M is the lowest of the 4 companies compared; the peer median is $855K.
- Its year-over-year change of -359.6% is the lowest of 3, against a peer median of +7467.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $53.38M | +14926.4% | +100.2% | 99.3% | |
| LTM Mar 2026 | $855K | +9.1% | — | 99.7% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$1.22M | -359.6% | — | — | |
| Peer median (excluding BOLD) | $855K | +7467.7% | +100.2% | 99.5% | |
Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.09M | 1.25M |
| Gross Profit | 0 | 0 | 0 | (1.09M) | (1.25M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 19.28M | 37.16M | 42.64M | 55.27M | 44.85M |
| Selling, General & Admin | 6.02M | 9.31M | 12.16M | 18M | 18.71M |
| Operating Expenses | 25.3M | 46.47M | 54.8M | 72.18M | 62.3M |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| EBITDA | (24.53M) | (44.96M) | (48.48M) | (64.28M) | (56.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (25.3M) | (46.47M) | (54.8M) | (73.27M) | (63.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 96K | 668K | 5.28M | 7.89M | 5.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 91K | 568K | 5.36M | 7.9M | 5.36M |
| Income Before Tax | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| EPS (Diluted) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| Weighted Avg Shares | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M |
| Weighted Avg Shares (Diluted) | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M |
Boundless Bio, Inc.
NASDAQ:BOLD
Intrinsic Alpha fair value
Locked
Current Price
$2.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.